Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation

Browse by...

Deposit

Highlights

More informations

Title		Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation
Authors		Terzic, Julie Seipel, Amanda Dubuisson, Jean Tille, Jean-Christophe Tsantoulis, Petros Addeo, Alfredo Labidi-Galy, Sana Intidhar
Published in		Gynecologic Oncology Reports. 2020, vol. 33, p. 100600
Abstract		•Metastatic CSMD3 mutated HGSOC showed objective and sustained response to pembrolizumab.•The tumor was massively infiltrated by CD8+ T cells while PD-L1 TPS was at 10%.•CSMD3 mutated HGSOC showed up-regulation of CCL5 and CXCL9.
Identifiers		DOI: 10.1016/j.gore.2020.100600 PMID: 32613071
Full text		Article (Published version) (1.6 MB) - Free access
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine Faculté de médecine / Section de médecine fondamentale / Département de pathologie et immunologie Faculté de médecine / Section de médecine clinique / Département de pédiatrie, gynécologie et obstétrique
Research group		Métastases du foie (657)
Citation (ISO format)		TERZIC, Julie et al. Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation. In: Gynecologic Oncology Reports, 2020, vol. 33, p. 100600. doi: 10.1016/j.gore.2020.100600 https://archive-ouverte.unige.ch/unige:146865

29 hits

14 downloads

Deposited on : 2020-12-22

Export document

Archive ouverte UNIGE